Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-0.37	-15.49	-21.38	-14.99	-6.52
Depreciation & Amortization	0.66	0.66	0.66	0.76	1.28
Other Amortization	-	-	-	-	0.19
Loss (Gain) From Sale of Assets	-	-	-	0	0.02
Stock-Based Compensation	0.16	0.81	1.35	1.95	0.98
Other Operating Activities	0.12	-2.12	0.15	1.15	-2.82
Change in Accounts Receivable	0.11	0.3	4.14	-0.03	0.03
Change in Accounts Payable	-0.92	0.8	0.37	0.68	-0.05
Change in Other Net Operating Assets	0.77	0.49	0.21	-4.38	1.39
Operating Cash Flow	0.08	-14.68	-14.64	-14.99	-5.65
Capital Expenditures	-	-	-	-0	-0
Sale of Property, Plant & Equipment	-	-	-	0.12	0.03
Investment in Securities	-	-	-	0.3	-0.09
Other Investing Activities	-	-	-	0.01	0
Investing Cash Flow	-	-	-	0.43	-0.06
Long-Term Debt Repaid	-	-	-	-0.12	-8.9
Net Debt Issued (Repaid)	-	-	-	-0.12	-8.9
Issuance of Common Stock	1.53	10.11	3.86	22.66	32.87
Other Financing Activities	-	5	-	-3.94	-0.31
Financing Cash Flow	1.53	15.11	3.86	18.6	23.66
Foreign Exchange Rate Adjustments	-0	0.08	-0.24	-0.55	-0.01
Net Cash Flow	1.6	0.5	-11.02	3.49	17.93
Free Cash Flow	0.08	-14.68	-14.64	-14.99	-5.65
Free Cash Flow Margin	0.49%	-	-	-359.30%	-812.46%
Free Cash Flow Per Share	0.05	-17.64	-0.01	-0.01	-0.01
Cash Interest Paid	0.02	0.03	-	0.03	0.54
Cash Income Tax Paid	-	0.05	-	-	-
Levered Free Cash Flow	0.46	-7.96	-6.7	-8.19	-2.14
Unlevered Free Cash Flow	0.46	-7.96	-6.7	-8.18	-1.66
Change in Working Capital	-0.5	1.45	4.58	-3.86	1.22

Updated Sep 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q